Published: BOPA Delphi consensus guidelines – Co-infusion of trometamol-containing calcium folinate (Leucovorin) with systemic anti-cancer treatments

The BOPA Guidelines, Advocacy And Publications Committee is pleased to announce that the British Oncology Pharmacy Association Delphi consensus guidelines is now published on the Journal of Oncology Pharmacy Practice.

 

Polwart C, Root T, Tezcan S, et al. British Oncology Pharmacy Association Delphi consensus guidelines: Co-infusion of trometamol-containing calcium folinate (Leucovorin) with systemic anti-cancer treatments. Journal of Oncology Pharmacy Practice. 2024;0(0). doi:10.1177/10781552241243360

The article is available here: https://doi.org/10.1177/10781552241243360

The full article can be accessed by ISOPP members via society complimentary access. Effective as of January 1, 2024, there is no fee for ISOPP membership for all existing and new members regardless of country. Click to find out more or to join ISOPP.

 

Huge congratulations to the following BOPA members:

Calum Polwart mBOPA

Tim Root fBOPA

Songül Tezcan

Bill Wetherill mBOPA

Chloë Waterson mBOPA

Bruce Burnett mBOPA

Rena Chauhan mBOPA

Ibrahim Al-Modaris mBOPA

Latest News

By BOPA Research Committee on 27th April 2025

SURVEY: Understanding Clinicians’ perceptions of a Decision Support tool for Lung Cancer Treatment

Dear BOPA member, Tarini Deleep and Dr Pinkie Chambers from University College London are developing a risk prediction model to help identify patients with incurable Non Small Cell Lung Cancer,…

Read article
By BOPA on 27th April 2025

Further monographs for use of immunosuppressants in Immune-related adverse events (irAEs)

Earlier this year the BOPA Immunotherapy Group wrote, and published, four monographs to help health care professionals care for patients with immune-related adverse events. As a group we are pleased…

Read article
By BOPA Committee on 27th April 2025

Women for Oncology UK Spring Webinar

The Spring webinar for Women for Oncology UK is on the 16th May, to sign up click the link below. Women For Oncology UK Spring Webinar Tickets, Wed 14 May…

Read article
By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article